Atinvicitinib - CAS 2169273-59-8

Atinvicitinib, a selective Janus kinase (JAK) inhibitor, demonstrates high specificity for Janus kinase 1 (JAK1), consequently inhibiting downstream cytokine signaling pathways that rely on JAK1 enzymatic activity. Atinvicitinib modulates a wide range of cytokines that are implicated in itch responses, allergic reactions, and inflammatory conditions, making it a significant research tool for studying cytokine-mediated immune processes as well as therapeutic modulation of allergic and inflammatory diseases.

JAK

JAK/STAT signaling, Chromatin/Epigenetic, Tyrosine Kinase/Adaptors, Angiogenesis, Stem Cells

2169206

0.9936

C16H17FN6O3

360.35

COc1cc(Nc2nn(cc2C(N)=O)[C@H]2COCC[C@@H]2C#N)cc(F)n1

-20°C

Ice Packs

Small Compound